Hudson Bay Capital Management LP Purchases 128,256 Shares of Astrazeneca Plc $AZN

Hudson Bay Capital Management LP raised its position in Astrazeneca Plc (NYSE:AZN) by 40.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 444,874 shares of the company’s stock after purchasing an additional 128,256 shares during the period. Hudson Bay Capital Management LP’s holdings in Astrazeneca were worth $34,131,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of AZN. Triumph Capital Management acquired a new position in shares of Astrazeneca during the third quarter worth about $25,000. Rakuten Investment Management Inc. acquired a new stake in Astrazeneca in the 3rd quarter valued at approximately $31,000. VSM Wealth Advisory LLC acquired a new stake in Astrazeneca in the 2nd quarter valued at approximately $33,000. JPL Wealth Management LLC bought a new stake in Astrazeneca in the 3rd quarter valued at approximately $35,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in Astrazeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after acquiring an additional 275 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AZN shares. Barclays reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday. Wall Street Zen downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Thursday, March 12th. Finally, Morgan Stanley reissued an “overweight” rating and set a $103.00 price target on shares of Astrazeneca in a research report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

Astrazeneca Trading Down 1.5%

Shares of Astrazeneca stock opened at $188.42 on Thursday. The company has a market cap of $292.22 billion, a PE ratio of 20.88, a P/E/G ratio of 1.44 and a beta of 0.32. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a 12-month low of $122.48 and a 12-month high of $212.71.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. Astrazeneca’s dividend payout ratio is 66.26%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.